Eye Infections Treatment Market by Competitive Landscape, SWOT Analysis, Opportunities and Challenges, Growth by 2030

Increasing prevalence of eye infections due to ocular surgical procedures is primarily shaping eye infection treatment market. A recent Future Market Insights (FMI) report forecasts that even though the eye infection treatment market would continue to experience a downtrend throughout 2022 due to COVId-19 pandemic, revenues would reach US$ 10 Bn by the end of 2030. Post-operative ocular infections remain among the most common eye infection types, says the FMI study.

Rising Caseloads

Caseloads of ocular surgical conditions such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are growing due to sedentary lifestyle habits, and expanding geriatric cohort. According to the US statistics 2021, cataracts affect over 24 million Americans aging at least 40 years.

By age 75, about half of the Americans suffer from cataract. Further, diabetic retinopathy affects nearly 7.7 million Americans aging at least 40 years. In similar fashion, there were 48,229 corneal transplants performed in the US in 2015.

Demand for eye infection treatment will continue to receive a strong impetus from increasing awareness about different eye infection types and availability of treatment, further complemented by technological advancements on ophthalmology.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1300

Key Takeaways of Eye Infection Treatment Market Study

• Antibiotics would contribute over 55% revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
• Eye drop sales capture over 60% market share in the eye infection treatment market.
• Conjunctivitis would account for a third of eye infection treatment demand through 2030.
• Bacterial infections continue to account for over 3/5^th market share.
• Hospitals and retail pharmacies collectively generate over 70% total returns to shareholders.
• Increasing rate of eye surgeries and rising usage of contact lenses continue to push North American market. European market would be upheld by the expanding geriatric pool.

Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic

The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections.

According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.

Development and Licensing Deals with Multiple Commercialization Partners

Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies.

For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in Chinese market for ZERVIATE.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-1300

Key Segments:

By Drug Class :

• Antibiotics
  • Sulfonamides
  • Macrolides
  • Erythromycin
  • Chloramphenicol
  • Aminoglycosides
  • Fluoroquinolones
  • Vancomycin
  • Tetracyclines
• Antivirals
  • Thymidine-Based Nucleoside Analogues (Trifluridine)
  • Thymidine Phosphorylase Inhibitors (Trifluridine)
  • Acyclic Nucleoside Analogue of 2’Deoxyguanasine (Ganciclovir)
  • Acyclic Guanine Nucleoside Analog (Acyclovir)
  • Others
• Antifungals
  • Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
  • Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))
  • Pyrimidines
  • Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
  • Others
• Antihistamines
• Corticosteroids
• Glucocorticoids

By Dosage Form :

• Eye Infections Treatment Tablets
• Eye Infections Treatment Capsules
• Eye Infections Treatment Ophthalmic Ointments
• Eye Infections Treatment Eye Drops
• Others

By Indication :

• Eye Infections Treatment for Conjunctivitis
• Eye Infections Treatment for Keratitis
• Eye Infections Treatment for Endophthalmitis
• Eye Infections Treatment for Blepharitis
• Eye Infections Treatment for Stye or Sty (Hordeolum)
• Eye Infections Treatment for Uveitis
• Eye Infections Treatment for Cellulitis
• Eye Infections Treatment for Ocular Herpes

By Causative Agent :

• Virus
• Bacteria
• Fungus
• Allergens

By Distribution Channels :

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

By Region :

• North America Eye Infections Treatment Market
• Latin America Eye Infections Treatment Market
• Europe Eye Infections Treatment Market
• East Asia Eye Infections Treatment Market
• South Asia & Pacific Eye Infections Treatment Market
• Middle East & Africa (MEA) Eye Infections Treatment Market

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-1300

Know More About FMI’s Eye Infection Treatment Market Study

Eye infection treatment market, a new study from Future Market Insights, opines on eye infections treatment from 2015 – 2021 and presents demand projections from 2022 – 2030 on the basis of; drug class (antibiotics, antivirals, antifungals, antihistamines, corticosteroids, and glucocorticoids), dosage form (tablet, capsule, ophthalmic ointment, and eye drops), indication (conjunctivitis, keratitis, endophthalmitis, blepharitis, stye or sty (hordeolum), uveitis, cellulitis, and ocular herpes), causative agent (virus, bacteria, fungus, and allergens) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and drug stores) across seven prominent regions.

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs